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Abstract
Nef is a multifunctional HIV-1 protein that accelerates progression to AIDS, and enhances the infectivity of progeny viruses
through a mechanism that is not yet understood. Here, we show that the small molecule compound 2c reduces Nef-
mediated viral infectivity enhancement. When added to viral producer cells, 2c did not affect the efficiency of viral
production itself. However, the infectivity of the viruses produced in the presence of 2c was significantly lower than that of
control viruses. Importantly, an inhibitory effect was observed with Nef
+ wild-type viruses, but not with viruses produced in
the absence of Nef or in the presence of proline-rich PxxP motif-disrupted Nef, both of which displayed significantly
reduced intrinsic infectivity. Meanwhile, the overexpression of the SH3 domain of the tyrosine kinase Hck, which binds to a
PxxP motif in Nef, also reduced viral infectivity. Importantly, 2c inhibited Hck SH3-Nef binding, which was more marked
when Nef was pre-incubated with 2c prior to its incubation with Hck, indicating that both Hck SH3 and 2c directly bind to
Nef and that their binding sites overlap. These results imply that both 2c and the Hck SH3 domain inhibit the interaction of
Nef with an unidentified host protein and thereby reduce Nef-mediated infectivity enhancement. The first inhibitory
compound 2c is therefore a valuable chemical probe for revealing the underlying molecular mechanism by which Nef
enhances the infectivity of HIV-1.
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Introduction
Nef is a 25- to 30-kDa protein with no catalytic activity encoded
by the HIV-1 genome [1–4]. Studies of HIV-1-infected patients
have demonstrated Nef to be a critical determinant of the
progression to AIDS: HIV-1 strains without an intact nef gene
were frequently isolated from non-progressive long-term survivors
[5,6]. A subsequent study of HIV-1 transgenic mice confirmed the
pathogenetic activity of Nef: targeted expression of the entire
coding sequence of HIV-1 in CD4
+ T cells and macrophages
caused a severe AIDS-like disease in mice, which was completely
abolished by disruption of the nef gene [7].
Nef is multifunctional. For instance, it accelerates the endocy-
tosis of CD4 [8,9], the primary entry receptor for HIV-1, which
allows efficient viral release from host cells [1–4]. Nef also reduces
the surface expression of MHC I through multiple mechanisms
[10–13], which diminishes the recognition of infected cells by
CTL [1–4]. Nef is also known to activate the Src kinase Hck
[14–16], which causes an impaired macrophage response to the
cytokine M-CSF [17,18] or triggers cell fusion of HIV-1-infected
macrophages [19]. Another hallmark function of Nef is the
enhancement of the intrinsic infectivity of progeny viruses. This
function of Nef is independent of CD4 downregulation and
requires the presence of Nef in viral producer cells [20–23].
Moreover, this function appears to depend on an early step of the
target cell infection process, as Nef is dispensable for the infectivity
of HIV-1 pseudotyped with vesicular stomatitis virus glycoprotein
VSV-G [24,25]. However, Nef does not affect viral assembly
or maturation, and it is still unclear how Nef enhances viral
infectivity [26].
Thus far, only a few chemical compounds that interfere with the
functions of Nef have been identified. Among them, a series of
guanidine alkaloid analogs were found to be too toxic for cell-
based assays [27]. A unique diphenylfuropyrimidine and its
analogs were identified to be strong inhibitors of the Nef-
dependent activation of Hck, but their primary target seemed to
be Hck not Nef [28]. In contrast, the chemical compounds D1 and
2c directly target Nef. Betzi et al. identified D1 and showed that it
reduced Nef-mediated MHC I, but not CD4, downregulation in a
dose-dependent manner [29]. Subsequently, we identified 2c, the
structure of which is distinct from that of D1, and showed that it
almost completely inhibited the Nef-dependent activation of Hck
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CD4, downregulation [31]. The fact that 2c has the inhibitory
effect on MHC I downregulation and Hck activation, but not on
CD4 downregulation, agrees with the finding that MHC I
downregulation and Hck activation are mediated by overlapping
motifs or amino acids of Nef, which are distinct from those
required for CD4 downregulation [3,9,14,18]. However, none of
these compounds have been tested for their ability to interfere with
the enhancement of viral infectivity by Nef.
In contrast to its requirement for elevated in vivo viral load
[5,6], Nef is not essential for viral replication in ex vivo cell
cultures. Nonetheless, Nef significantly enhances viral replication
in primary CD4
+ T cells and macrophages that have been
exposed to HIV-1 prior to their stimulation with mitogens
[32,33], a function of Nef that is likely determined by
enhancement of the initial infection with cell-free HIV-1 [34].
In this regard, a compound that can reduce viral infectivity would
be a valuable chemical probe for revealing the underlying
mechanism of this function of Nef. In this study, we identified 2c
as the first small compound that has an inhibitory effect on Nef-
mediated HIV-1 infectivity enhancement and reported its
inhibitory mechanism.
Figure 1. The effect of 2c on the infectivity of NL43 wild-type and Nef-defective mutant viruses. (A) The chemical structure of 2c. (B) The
infectivity of the NL43 wild-type (WT) and Nef-defective mutant (DNef) viruses to the target TZM-bl cells was compared by varying the concentration
of p24 Gag protein and is expressed as a percentage of the value for the sample on the far left. Data are shown as the mean6SD of triplicate assays
and are representative of two independent experiments with similar results. (C) 2c was added to 293 cells producing NL43-WT or DNef viruses at the
indicated concentrations for 2 days, and the concentration of p24 Gag protein in the cell supernatants was determined by ELISA (bar graph). Data are
shown as the mean6SD of triplicate assays and are representative of two independent experiments with similar results. Alternatively, the producer
cells were lysed and analyzed for the expression of Gag and Nef by Western blotting (lower blots). The actin blot was used as a loading control. (D)
The infectivity of NL43-WT (upper) or DNef viruses (lower) produced by 293 cells in the absence or presence of the indicated concentrations of 2c was
determined using TZM-bl cells as the target cells. The WT and DNef viruses were inoculated by changing the p24 concentration (2 or 4 ng/ml and 8 or
16 ng/ml for the WT and DNef viruses, respectively) so that the two viruses were similarly infective to the target cells. Infectivity is expressed as a
percentage of the value for the sample on the far left. Data are shown as the mean6SD of triplicate assays and are representative of three
independent experiments with similar results. *p,0.05.
doi:10.1371/journal.pone.0027696.g001
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2c reduces the infectivity of wild-type HIV-1
We assessed the effect of the compound 2c (Fig. 1A) on Nef-
mediated infectivity enhancement using a standard single-round of
replication assay [21–23]. HIV-1 viruses were prepared by
transfecting HIV-1 proviral clones into 293 cells (producer cells),
and infectivity was analyzed by inoculating TZM-bl cells (target
cells) with defined amounts of p24 Gag protein of the resultant
viruses. We first used the proviral clone NL43 and a Nef-defective
mutant (DNef) and confirmed that the infectivity of the DNef
viruses was lower than that of the NL43 wild-type (WT) viruses
(Fig. 1B). When added to the producer 293 cells, 2c did not affect
the production of WT or DNef viruses, even at a high
concentration such as 75 mM (Fig. 1C): there was no significant
difference in the supernatant p24 Gag protein concentration
(upper graph) or the processing of the Gag polyprotein in the cells
(lower blots) between the control and 2c-treated cells. However,
we found that the infectivity of the WT viruses produced in the
presence of 2c was significantly lower than that of the control
viruses (Fig. 1D, upper). An inhibitory effect of 2c was detectable
at a minimal concentration of 25 mM. Importantly, no such
inhibition was observed for the DNef viruses, even at a high 2c
concentration (75 mM) (Fig. 1D, lower). In the experiment shown
in Fig. 1D, WT and DNef viruses were inoculated into TZM-bl
cells, and the concentration of p24 was adjusted (2 or 4 ng/ml and
8 or 16 ng/ml for WT and DNef viruses, respectively) so that the
two viruses were similarly infective to the target cells (see Fig. 1B).
As the supernatant of proviral plasmid-transfected 293 cells was
used as a viral stock, 2c was also present in the culture of target
cells (,5 mM). However, 2c did not reduce the infectivity when
added to the target cells at a high concentration (10 or 25 mM)
together with WT viruses produced in the absence of 2c (Fig. 2A),
suggesting that the presence of 2c in the producer cells was
essential for its inhibitory effect. Although 2c was added to the
producer cells immediately after transfection in Fig. 1D, the
inhibitory effect was also observed when 2c was added 24 h after
transfection (Fig. 2B). Importantly, 2c did not show any inhibitory
effect on the infectivity of Nef
+ HIV-1 viruses pseudotyped with
VSV-G (Fig. 2C), which was consistent with the finding that Nef
was dispensable for the infectivity of VSV-G-pseudotyped HIV-1
[24,25]. Therefore, these results indicated that 2c specifically
reduced the infectivity of the wild-type NL43 viruses produced in
the presence of Nef.
We also assessed the effect of 2c on viral replication. 2c
decreased by half in the number of viable peripheral blood
mononuclear cells after 9 days when used at 50 mM (data not
shown). On the other hand, 2c at the same concentration showed
no detectable toxicity to 293, TZM-bl, Jurkat T cells and
macrophages (data not shown). We therefore used Jurkat and
macrophages as target cells. As previously reported [28], the
replication of HIV-1 NL43 was independent of Nef in Jurkat T
cells (Fig. 3A). Accordingly, 2c failed to inhibit viral replication in
the cells (Fig. 3A). However, WT JRFL viruses replicated more
efficiently than DNef viruses in monocyte-derived macrophages,
and 2c significantly reduced the replication of WT viruses (Fig. 3B).
The result further supported the idea that the primary target of 2c
was Nef.
The inhibitory effect of 2c requires the proline-rich PxxP
motif of Nef
Next, we tested the inhibitory activity of 2c on the infectivity of
NL43 viruses with point mutations in Nef; i.e., R77A, K82A,
D86A, F90A, or G119L [35]. As shown, 2c reduced the infectivity
of all these viruses, although to a varying degree (Fig. 4A).
Interestingly, the intrinsic infectivity of the NL43-G119L viruses
was shown to be low [35] (also see Fig. 4A), but 2c further reduced
the infectivity of the mutant viruses to the level of the DNef viruses
Figure 2. Several features of the activity of 2c on viral infectivity. (A) 2c was added to the target TZM-bl cells at the indicated concentrations
together with the NL43 wild-type (WT) viruses produced in the absence of 2c. The amount of p24 inoculated was 4 or 8 ng/ml. The infectivity is
expressed as a percentage of the value for the sample on the far left. (B) 2c (50 mM) or the control DMSO was added to the producer 293 cells
immediately after transfection (0 h) or 24 h after transfection of the NL43 WT plasmid. The infectivity of the viruses was determined using TZM-bl
cells and is expressed as a percentage of the value for the sample on the far left. The amount of p24 inoculated was 4 ng/ml. (C) 2c (50 or 75 mM) or
the control DMSO was added to the producer 293 cells immediately after co-transfection of Env-defective NL43 plasmid and VSV-G expression
plasmid. The infectivity of the pseudotyped viruses was determined using TZM-bl cells and is expressed as a percentage of the value for the sample
on the far left. The amount of p24 inoculated was 4 or 8 ng/ml. (A–C) Data are shown as the mean6SD of triplicate assays and are representative of
two independent experiments with similar results. *p,0.05.
doi:10.1371/journal.pone.0027696.g002
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infectivity of the NL43 viruses in a Nef-dependent manner.
The dileucine motif of Nef (
164LL
165) that is required for CD4
downregulation is also required for the enhancement of infectivity
[3,36]. However, it was unlikely that the inhibitory activity of 2c
was mediated through the motif, as 2c did not inhibit CD4
downregulation [31]. On the other hand, Nef has another
characteristic motif; i.e., a proline-rich PxxP motif, and the
substitution of the proline residues for alanine residues (AxxA) is
known to result in reduced viral infectivity [3]. Thus, we tested
whether 2c further reduced the infectivity of Nef-AxxA viruses as it
did with G119L mutant viruses (see Fig. 4B). To test whether 2c is
also effective against Nef derived from an additional HIV-1 strain,
we used an HIV-1 JRFL construct in which nef gene was replaced
with that of the SF2 strain Nef or its AxxA mutant [30] in the
subsequent experiments. First, as expected, the infectivity of the
Figure 3. The effect of 2c on the replication of HIV-1. (A) Jurkat cells were infected with either the NL43 wild-type (WT) or Nef-defective (DNef)
viruses at the indicated concentrations of p24, and cultured in the presence (50 mM) or absence of 2c. AZT was also used at 5 mM. The concentration
of p24 in the supernatants (at day 5, 7 or 9) was determined by ELISA. Data are shown as the mean6SD of triplicate assays and are representative of
two independent experiments with similar results. (B) Peripheral blood monocyte-derived macrophages were obtained from two different donors,
infected with either the JRFL wild-type (WT) or Nef-defective (DNef) viruses at the indicated concentrations of p24, and cultured in the presence
(50 mM) or absence of 2c. AZT was also used at 5 mM. The concentration of p24 in the supernatants (at day 6, 9 or 12) was determined by ELISA. Data
are shown as the mean6SD of triplicate assays. *p,0.05.
doi:10.1371/journal.pone.0027696.g003
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viruses, although it was still higher than that of the DNef viruses
(Fig. 5A). As was the case with the NL43 viruses (see Fig. 1C), 2c
did not affect viral production in the JRFL-SF2 Nef viruses
(Fig. 5B): there was no change in the amount of p24 Gag protein in
the supernatants (upper graph), the processing of the Gag
polyprotein, or the expression of Nef or another viral protein,
Vif, (lower blots) between the control and 2c-treated cells.
Moreover, as was the case with the NL43 viruses (see Fig. 1D),
2c significantly reduced the infectivity of the produced JRFL-SF2
Nef WT viruses, but not that of the DNef viruses (Fig. 5C).
However, we found that 2c minimally affected the infectivity of the
Nef-AxxA mutant viruses (Fig. 5C, middle), which was in contrast
with the finding that it further reduced the infectivity of the Nef-
G119L mutant viruses (see Fig. 4B). These results suggested that
the inhibitory activity of 2c is mediated, at least in part, through
the proline-rich motif of Nef.
2c binds directly to Nef in a similar manner to the Hck
SH3 domain
Although 2c was the first small molecule to be found to reduce
the Nef-mediated infectivity of HIV-1, the overexpression of
mutant forms of Hck in viral producer cells was also reported to
result in reduced viral infectivity [37]. Hck is a cellular tyrosine
kinase, and its SH3 domain has been shown to bind to Nef with
high affinity [14–16], although its pathological significance is not
yet understood. It is also known that the SH3 domain forms an
intra-molecular interaction with the linker region of Hck [15,16]
(also see Fig. 6A). Thus, the SH3 domain of mutant Hck, which
lacks the linker region and the subsequent kinase domain (see
Fig. 6A, HckN), is devoid of the intra-molecular interaction, and is
thought to more efficiently bind to Nef and thereby reduce viral
infectivity. Indeed, when co-expressed with the NL43 proviral
clone, HckN and HckN-R151S, which carries a mutation in its
SH2 domain, but not HckN-W93F, which carries a mutation in its
SH3 domain, significantly reduced the infectivity of viruses
produced from the cells (Fig. 6B).
Based on these results, we hypothesized that 2c inhibits viral
infectivity in a similar manner to mutant Hck. To this end, we
examined whether 2c and Hck compete to bind to Nef using an in
vitro pull-down assay. First, we performed a pull-down assay with
various combinations of GST-Nef fusion proteins (Fig. 7A) and the
Hck proteins described above. As a result, we found that the wild-
type (WT) NL43 Nef bound to the wild-type (WT) Hck, HckN,
and HckN-R151S, but not Hck-W93F, which had a mutation in
its Nef-binding SH3 domain (Fig. 7B). In contrast, the PxxP motif-
disrupted AxxA mutant did not bind to any of these Hck proteins
(Fig. 7B), confirming that the pull-down system specifically
detected Nef-Hck binding. As the affinity of the SF2 strain Nef
for Hck was higher than that of NL43 strain Nef, which was due to
the different amino acid present within the PxxP motif (Figs. 7A
and B, NL43 Nef-TR mutant with a T71R substitution), we used
SF2 Nef in the following experiments. Among three different
competitive pull-down assays, the pre-incubation of Nef with 2c
most effectively inhibited the binding of Hck to Nef (Fig. 7C,
right). We therefore concluded that both the Hck SH3 domain
and 2c directly bind to Nef and that their binding sites overlap.
To further confirm the above-mentioned conclusion, we used a
GST fusion protein containing a 20-mer peptide derived from the
PxxP motif of SF2 Nef (Fig. 8A, SF2-PxxP). As shown, the
observed binding of the SF2-PxxP peptides to Hck was specific,
albeit weak, in comparison with that of the full-length Nef, since it
was detected with the wild-type Hck, HckN, and HckN-R151S,
but not with the Nef binding-deficient HckN-W93F (Fig. 8A).
Importantly, 2c inhibited the binding of Hck to the Nef-PxxP
peptide, and its inhibitory effect was more marked when the Nef-
PxxP peptide was pre-incubated with 2c prior to its incubation
with Hck (Fig. 8B). This result suggests that 2c binds to Nef, at
least in part, through the region including the PxxP motif, which is
consistent with the finding that unlike the wild-type viruses, the
Figure 4. The effect of 2c on the infectivity of NL43 viruses with point amino acid mutations in Nef. (A) The infectivity of the indicated
NL43 viruses produced by 293 cells in the absence or presence of 50 mM 2c was determined using TZM-bl cells as the target cells and is expressed as
a percentage of the value for the sample on the far left. The amount of p24 inoculated was 10 ng/ml. Wild-type (WT), Nef-defective (DNef), or viruses
with the indicated amino acid point mutations in Nef (R77A, K82A, D86A, F90A, or G119L) were used. (B) The infectivity of NL43 viruses with the
G119L mutation in Nef or DNef viruses produced by 293 cells in the absence or presence of 50 mM 2c was determined using TZM-bl cells as the target
cells and is expressed as a percentage of the value for the sample on the far left. The amount of p24 inoculated was 2, 8, or 32 ng/ml. (A, B) Data are
shown as the mean6SD of triplicate assays and are representative of two independent experiments with similar results. *p,0.05.
doi:10.1371/journal.pone.0027696.g004
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minimally affected by 2c (see Fig. 5C).
Finally, a computer-assisted simulation of the 2c-Nef docking
model supported the idea that 2c binds directly to Nef and
suggested that R77, K82, A83, D86, I87, F90, Q118, and Y120
(positions are based on the sequence of NL43 strain Nef) may be
responsible for this binding (Fig. 9). Among them, R77 lies within
the PxxP motif (–PVTPQVPLR
77P–, the proline residues are
Figure 5. The effect of 2c on the infectivity of SF2 wild-type, Nef-defective, and Nef PxxP motif-disrupted viruses. (A) The infectivity of
the SF2 wild-type (WT), Nef-defective (DNef), and Nef PxxP motif-disrupted viruses (AxxA) was compared by inoculating them into the target TZM-bl
cells at a concentration of 8 ng/ml p24 and is expressed as a percentage of the value for the sample on the far left. Data are shown as the mean6SD
of triplicate assays and are representative of two independent experiments with similar results. *p,0.05. (B) 2c was added to 293 cells producing SF2-
WT, DNef, or AxxA viruses at the indicated concentrations for 2 days, and the concentration of p24 Gag protein in the supernatants was determined
by ELISA (bar graph). Data are shown as the mean6SD of triplicate assays and are representative of two independent experiments with similar
results. Alternatively, the producer cells were lysed and analyzed for the expression of Gag, Nef, and Vif by Western blotting (lower blots). The actin
blot was used as a loading control. (C) The infectivity of SF2-WT (top), AxxA (middle), or DNef viruses (bottom) produced by 293 cells in the absence
or presence of the indicated concentrations of 2c was determined using TZM-bl cells as the target cells. The WT, AxxA, and DNef viruses were
inoculated by changing the concentration of p24 (8 ng/ml, 16 ng/ml, and 32 ng/ml for WT, AxxA and DNef viruses, respectively) so that these viruses
were similarly infective to the target cells. Infectivity is expressed as a percentage of the value for the sample on the far left. In the top panel, the
infectivity values of the AxxA and DNef viruses produced at the same concentration of p24 (i.e., 8 ng/ml) are also shown as a reference. In the middle
panel, the infectivity values of the DNef viruses produced at the same concentration of p24 (i.e., 16 ng/ml) are also shown. Data are shown as the
mean6SD of triplicate assays and are representative of three independent experiments with similar results. *p,0.05.
doi:10.1371/journal.pone.0027696.g005
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identified several residues in Nef that are responsible for its
binding to Hck, such as P72, P75, R77, A83, F90, W113, His116,
and Y120 [38]. Among them, R77, A83, F90, and Y120 were also
found in the 2c-Nef docking model (Fig. 9, underlined), supporting
the finding that 2c inhibits the binding of Hck to Nef or Nef PxxP
motif-derived peptides (Figs. 7C and 8B). In summary, the present
study revealed that the compound 2c reduced the infectivity of
HIV-1 viruses and suggested that its inhibitory activity is mediated
by its direct binding to Nef.
It remains to be determined exactly how 2c reduces Nef-
mediated infectivity enhancement. Given that both 2c and the
Hck SH3 domain bind directly to overlapping domains of Nef and
reduce viral infectivity, we speculate that their inhibitory effects
are due to the inhibition of the interaction of Nef with host
proteins (Fig. 10). One of the candidates for such a host protein is
p21-activated kinase 2, PAK2, the association of which depends
on the Nef PxxP motif [39]. However, we did not observe any
inhibitory effect of 2c on the association of Nef with PAK2 activity
or its downstream effector functions (data not shown), and the Nef-
PAK2 association is dispensable for the enhancement of infectivity
by the viral protein [40]. Another candidate is the GTPase
dynamin 2 whose interaction with Nef was implicated in
enhancing viral infectivity [41]. However, again, we did not
observe any significant inhibitory effect of 2c on the binding of Nef
to dynamin 2, which was assessed using a co-immunoprecipitation
assay (data not shown). Thus, the inhibitory activity of 2c observed
in this study appears to be independent of these host proteins. The
inhibitory compound 2c is a useful chemical probe for investigat-
ing the underlying molecular mechanism by which Nef enhances
the infectivity of HIV-1, and in particular, for identifying the host
proteins involved in the process.
Recently, a single-domain antibody (sdAb) that binds to Nef was
reported [42]. Although the binding domains in Nef remained
unclear, anti-Nef sdAb was also shown to reduce in vitro viral
infectivity [42]. Therefore, to clarify whether viral infectivity
enhancement by Nef accounts for the high in vivo viral load
observed in the presence of Nef, it is necessary to test the effects of
2c, a more potent analog, and/or the anti-Nef sdAb in animal
models such as HIV-1-infected humanized mice.
Materials and Methods
The compound 2c preparation
Some of the 2c was prepared by Kyowa Hakko Kogyo (Tokyo,
Japan), as described previously [43], whilst the rest (a large
quantity) was prepared by Sai Advantium Pharma (Hyderabad,
India). Both preparations were dissolved in DMSO and had an
equivalent inhibitory effect on HIV-1 infectivity (data not shown).
Proviral plasmids
The provial NL43 plasmid and its derivatives, which had
mutations in the Nef gene (DNef, R77A, K82A, D86A, F90A, and
G119L), were prepared as described previously [35]. The Env-
defective mutant (pNL-Kp) and VSV-G expression plasmid were
prepared as described previously [44]. The proviral JRFL plasmid
was provided by Y. Koyanagi (Kyoto University, Kyoto, Japan)
[45]. We also prepared the proviral JRFL plasmid, in which the
Nef gene was disrupted (DNef) or replaced with the PxxP motif-
disrupted AxxA mutant [30].
Hck plasmids
The p56Hck cloned into the pcDNA3.1 vector (Invitrogen) was
prepared as described previously [18]. The mutant forms of Hck
cloned into the pCAGGS vector (HckN, Hck-R151S, and Hck-
W93F; see Fig. 6A) were provided by M. Matsuda (Kyoto
University, Kyoto, Japan) [37].
GST fusion plasmids
The control GST and GST-Nef fusion plasmids (the wild-type
NL43, NL43 Nef-TR mutant, NL43 Nef-AxxA, and the wild-type
SF2; see Fig. 7) were prepared as described previously [30]. We also
prepared a GST-SF2 Nef-PxxP plasmid, which expressed a 20-mer
peptide derived from the PxxP motif of SF2 Nef (see Fig. 8). The
cDNA containing the motif was amplified by PCR using the
following primers (59-GGATCCGTGGGTTTTCCAGT-39 and
59-GTCGACCTATAAAGCTGCCT-39), cloned into the pCR2.1
vector (Invitrogen), sequenced using the BigDye Terminator v3.1
Figure 6. The effects of the overexpression of mutant forms of
Hck on viral infectivity. (A) The mutant forms of Hck used are shown
schematically. HckN lacks the kinase domain and the two intra-
molecular interactions present in the wild-type (WT) Hck. HckN-based
HckN-R151S and HckN-W93F have amino acid substitutions in their SH2
and SH3 domain, respectively. (B) The 293 cells were transfected with
the NL43 wild-type proviral plasmid or co-transected with the indicated
amount of plasmid (HckN, HckN-R151S, or HckN-W93F). The infectivity
of the viruses produced in the supernatants was determined using
TZM-bl cells as the target cells and is expressed as a percentage of the
value for the sample on the far left (bar graph). The amount of p24
inoculated was 8 ng/ml. Alternatively, the producer 293 cells were lysed
and analyzed for the expression of the mutant Hck proteins by Western
blotting (blot).
doi:10.1371/journal.pone.0027696.g006
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3100 Genetic Analyzer (Applied Biosystems), and cloned into the
pGEX-6P-1 bacterial expression vector (GE Healthcare).
Virus preparation
HEK293 cells (Invitrogen) were maintained in DME medium
supplemented with 10% FCS and used as viral producer cells. The
293 cells were seeded onto 12-well tissue culture plates at a density
of 1.8610
5 cells/well and transfected with 1.6 mg/well of various
proviral HIV-1 plasmids using 4 ml/well Lipofectamine 2000
reagent (Invitrogen). To prepare VSV-G-pseudotyped viruses (see
Fig. 2C), cells were transfected with 0.5 mg/well Env-defective
mutant plasmid (pNL-Kp) and 1.0 mg/well VSV-G expression
plasmid. In a selected experiment (see Fig. 6B), the cells were co-
transfected with 0.8 mg/well pNL43 plasmid and 0.2, 0.4, or
0.8 mg/well of one of the mutant forms of Hck (HckN, HckN-
R151S, or HckN-W93F). The total amount (1.6 mg/well) of the
plasmid was normalized using the pCAGGS empty vector. After
6 h of transfection, the culture medium was replaced with fresh
medium, and the cells were cultured for an additional 48 h in the
presence or absence of 2c at the indicated concentrations. In a
selected experiment (see Fig. 2B), 2c was added to the culture 24 h
after transfection. Then, the supernatants containing the viruses
were clarified by brief centrifugation, and viral production was
assessed by measuring the concentration of p24 Gag protein in the
supernatants using the RETROtek p24 Antigen ELISA kit
(ZeptoMetrix). Viral production was also assessed by analyzing
the expression of viral proteins in the cells by Western blotting.
The preparation of the total cell lysates and Western blotting were
performed essentially as described previously [17,18,30]. Briefly,
the cells were lysed on ice with Nonidet P-40 lysis buffer (1%
Nonidet P-40, 50 mM Tris, and 150 mM NaCl) containing
protease inhibitors (1 mM EDTA, 1 mM PMSF, 1 mg/ml
aprotinin, 1 mg/ml leupeptin, and 1 mg/ml pepstatin). Total cell
lysates were then subjected to Western blotting. The antibodies
used were as follows: anti-Gag (#65-004; BioAcademia, Osaka,
Japan), anti-Nef (#2949; NIH AIDS Research & Reference
Program), anti-Vif (#319; NIH AIDS Research & Reference
Program), and anti-actin (#C-2; Santa Cruz). The detection was
performed with HRP-labeled secondary antibodies (GE Health-
Figure 7. The effect of 2c on binding between Nef and Hck. (A) The Nef proteins fused to GST are shown schematically. In addition to the wild-
type (WT) SF2 and NL43 strain Nef, the NL43-TR mutant, which contained a T71R amino acid substitution, and another NL43 AxxA mutant, in which
the PxxP motif was disrupted (P72A and P75A substitutions), were used. (B) The resins to which the control GST or indicated GST-Nef fusion proteins
were bound were incubated with the lysates of 293 cells expressing the indicated Hck protein. The amount of Hck bound to the resins was
determined by Western blotting (pull-down assay). To confirm the equal expression of these Hck proteins in the 293 cells, equal amounts of each cell
lysate were analyzed (Input Hck). Moreover, the amounts of the GST and GST-Nef fusion proteins bound to the resins were verified by the elution
from the resins followed by SDS-PAGE/Coomassie brilliant blue (CBB) staining. (C) Three different competitive pull-down assays were performed. In
the experiment shown in the left panel, the resins to which the GST-SF2 Nef fusion proteins were bound were incubated with the lysates obtained
from the 293 cells expressing the wild-type Hck for 3 h, and then 2c was added to the mixture at the indicated concentration. In the experiment
shown in the middle panel, the resins to which the GST-SF2 Nef fusion proteins were bound were incubated with the lysates of 293 cells expressing
the wild-type Hck and the indicated concentration of 2c. In the experiment shown in the right panel, the resins to which the GST-SF2 Nef fusion
proteins were bound were first incubated with the indicated concentration of 2c for 4 h and then washed to remove unbound 2c. Then, the resins
were incubated with the lysates of 293 cells expressing the wild-type Hck. The amount of Hck bound to the resins was determined by Western
blotting (upper blots). The GST-Nef blot was used as a loading control (lower blots). Data shown are representative of two independent experiments
with similar results.
doi:10.1371/journal.pone.0027696.g007
Small Molecule Inhibition of HIV-1 Infectivity
PLoS ONE | www.plosone.org 8 November 2011 | Volume 6 | Issue 11 | e27696care), the Immunostar LD Western blotting detection reagent
(Wako, Osaka, Japan), and an image analyzer (ImageQuant LAS
4000; GE Healthcare).
Infectivity assay
TZM-bl cells (NIH AIDS Research & Reference Program) were
maintained in DME medium supplemented with 10% FCS and
used as viral target cells. TZM-bl cells were seeded onto 96-well
tissue culture plates at a density of 6610
3 cells/well and challenged
with serially diluted viruses normalized for the concentration of
p24 Gag protein. The supernatant of the proviral plasmid-
transfected 293 cells was used as a viral stock and diluted with
DME medium containing 10% FCS and 20 mg/ml DEAE-
dextran (MP Biomedicals, Solon, OH). The diluted viruses were
then added to the target cells (150 ml/well) overnight, and the
culture medium was replaced with fresh DME medium containing
10% FCS and incubated for 48 h. In a selected experiment (see
Fig. 2A), 2c was added to TZM-bl cells together with the diluted
viruses. Viral infectivity was assessed by measuring the HIV-1 Tat-
mediated induction of b-galactosidase activity in the target cells
using a b-Galactosidase Enzyme Assay System (Promega). The
absorbance of the wells was measured at 420 nm using a
Multiskan microplate reader (Thermo Electron).
Replication assay
The replication assay with macrophages was performed essen-
tially as described previously [46]. Heparinized venous blood was
collected from healthy donors, after informed consent was obtained
in accordance with the Declaration of Helsinki. The approval for
this study was obtained from the Kumamoto University Medical
Ethical Committee. Mononuclear cells obtained using LSM reagent
(MP Biomedicals) were suspended into RPMI1640 medium-1%
FCS at 1610
6 cells/ml and seeded into 24-well plates. Monocytes
were enriched by adherence to plates for 1 h at 37uC, and non-
adherent cells were removed by extensive washing with PBS. Then,
the adherent monocytes were differentiated into macrophages by
culturing with RPMI1640-10% FCS containing 100 ng/ml rhM-
CSF (a gift from Morinaga Milk Industry, Kanagawa, Japan). After
3 days, the cultures were replaced with fresh complete media and
incubated for another 3 days. The purity of the day 6-macrophages
prepared by this method was routinely more than 95% when
assessed by the expression of CD14 (data not shown). Then,
macrophages were incubated with 250 ml of the 293 cell
supernatants containing JRFL HIV-1 viruses for 2 h at 37uC.
Either 2c or DMSO was added to the incubation together with the
diluted viruses. AZT (NIH AIDS Research & Reference Program)
wasused asapositivecontrol.Thecellswerewashedtwicewith PBS
toremoveunbound virusesand culturedwithRPMI1640-10%FCS
containingrhM-CSFinthepresenceorabsenceof2corAZT.One-
half of the culture media was replaced with the complete media
every 3 days. The culture supernatants collected at day 6, 9 and 12
were analyzed for the concentration of p24 Gag proteins by ELISA
to monitor viral replication.
Jurkat cells were also used in this study. The cell pellet (1610
6
cells) were incubated with 500 ml of the 293 cell supernatants
containing NL43 viruses for 2 h at 37uC. Either 2c or DMSO was
added to the incubation together with the diluted viruses. AZT
was used as a positive control. The cells were washed twice with
PBS, resuspended into 1 ml of RPMI1640-10% FCS, and
cultured for 3 days in the presence or absence of 2c or AZT.
Then, the culture were diluted (1/5) with RPMI1640-10% FCS,
and cultured for another 2 days in the presence or absence of 2c or
AZT. The concentration of p24 in the culture supernatants of day
5, 7 and 9 was analyzed as above.
GST pull-down assay
The control GST and GST-Nef fusion proteins cloned in
the pGEX-6P-1 vector were expressed in E. coli BL21 cells
Figure 8. The effect of 2c on the binding between Nef PxxP
motif-containing peptides and Hck. (A) The Nef peptide fused to
GST is shown schematically. The 20 amino acid peptide derived from the
PxxP motif of SF2 Nef was used (the proline residues are underlined). The
resinsto whichthecontrol GST, GST-SF2 Nef-PxxPpeptides (SF2-PxxP), or
GST-intact SF2 Nef (SF2-WT) fusion proteins were bound were incubated
with the lysates of 293 cells expressing the indicated Hck protein. The
amount of Hck bound to each resin was determined by Western blotting
(Pull-down). To verify the equal expression of these Hck proteins in the
293 cells, equal amounts of each cell lysate were analyzed (Input Hck).
Moreover, the amounts of the GST and GST-Nef fusion proteins bound to
the resinswere verified by eluting from the resinsfollowed by SDS-PAGE/
Coomassie brilliant blue (CBB) staining. (B) Two different competitive
pull-down assays were performed. In the experiment shown in the left
panel, the resins to which the GST-SF2 Nef-PxxP peptides were bound
were incubated with the lysates of 293 cells expressing the wild-type Hck
and the indicated concentration of 2c. In the experiment shown in the
right panel, the resins to which the GST-SF2 Nef-PxxP peptides were
bound were incubated with the indicated concentrations of 2c for 4 h
and then washed to remove unbound 2c. Then, the resins were
incubated with the lysates of 293 cells expressing the wild-type Hck. The
amount of Hck bound to the resins was determined by Western blotting
(upper blots). The GST-Nef blot was used as a loading control (lower
blots). Data shown are representative of two independent experiments
with similar results.
doi:10.1371/journal.pone.0027696.g008
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50 mg/ml ampicillin, before being induced with 1 mM IPTG
(Sigma). The expression-induced cells were harvested and lysed
with BugBuster Protein Extraction Reagent containing 1 U/ml
rLysozyme and 25 U/ml Benzonase Nuclease (all from Novagen).
The cleared lysates were then incubated with GST-Bind Resin
(Novagen). After extensive washing with GST Bind/Wash Buffer
(Novagen), the resin was incubated with the total cell lysate of the
293 cells transfected with the expression plasmid for Hck for 12 h.
In the competitive pull-down assay, we employed the following 3
protocols: (1) the concurrent addition of 2c and Hck-containing
lysates to the GST-Nef-bound resin, (2) the addition of Hck-
containing lysates for 3 h followed by the addition of 2c, (3) the
addition of 2c at the indicated concentrations for 4 h followed by
the addition of the Hck-containing lysates. The incubation of the
above mixtures was carried out at 4uC in Nonidet P-40 lysis buffer
(1% Nonidet P-40, 50 mM Tris, and 150 mM NaCl) containing
protease inhibitors (1 mM EDTA, 1 mM PMSF, 1 mg/ml
aprotinin, 1 mg/ml leupeptin, and 1 mg/ml pepstatin). After
extensive re-washing with complete Nonidet P-40 lysis buffer,
the resin was boiled with SDS-PAGE sample buffer, and the
eluates were analyzed for the presence of Hck by Western blotting
with anti-Hck antibodies (clone 18; Transduction Laboratories).
The 2c-Nef docking model
We predicted the complex structures of Nef and 2c by
homology modeling and docking simulation using the Molecular
Operating Environment (MOE) ver. 2007.09. (Chemical Com-
puting Group, Canada). First, homology modeling [47–49] was
used to construct the model structure of HIV-1 Nef SF2 strain
using its NMR structure (PDB code: 2NEF) [50] as a template.
During the modeling, energy calculations were performed with the
AMBER ff99 force field [51] and the GB/VI implicit solvent
energy function [52]. Next, docking simulation of 2c with the
homology model of Nef was achieved with the ASEDock module
[53]. The initial structure of 2c was generated with the Molecular
Builder module. Then, we searched for the binding site of 2c with
the Site-Finder module. During the simulation, the energy
calculations were performed with the MMFF94x force field
[54,55] and the GB/VI implicit solvent energy function [52].
Figure 9. The 2c-Nef docking model. The amino acids that are predicted to be involved in the interaction between Nef and 2c are indicated. The
positions of these amino acids in the NL43 strain and SF2 strain are shown. The amino acids predicted to interact with the Hck SH3 domain are
underlined [38].
doi:10.1371/journal.pone.0027696.g009
Figure 10. A model of the inhibitory effect of 2c. Both 2c and the Hck SH3 domain bind directly to Nef and reduce viral infectivity, probably by
inhibiting the interaction of Nef with an unidentified cellular protein(s).
doi:10.1371/journal.pone.0027696.g010
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atoms around 4.5 A ˚ of the ligand binding site in Nef was
restrained with a harmonic potential of 100 kcal/mol/A ˚ 2, while
the atoms in compound 2c were not constrained. In this study, the
structure with the lowest score was selected for the model.
Statistical analysis
The statistical significance of differences between assay groups
was determined using Mann-Whitney U test. p values less than
0.05 were considered significant.
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